首页> 外文期刊>Annals of Clinical Biochemistry >N-Terminal pro-Brain natriuretic peptide as a potential non-invasive marker of cardiac transplantation rejection
【24h】

N-Terminal pro-Brain natriuretic peptide as a potential non-invasive marker of cardiac transplantation rejection

机译:N端前脑利钠肽是心脏移植排斥反应的潜在非侵入性标志物

获取原文
获取原文并翻译 | 示例
       

摘要

Transplantation is the main palliative treatment for patients with heart failure. Clinical signs of cardiac rejection can be very non-specific or even absent. Thus, successfull management relies on early diagnosis, ideally before the onset of clinical features of cardiac dysfunction. Although endomyocardial biopsy (EMB) is the reference diagnostic method, several non-invasive methods have been proposed to reduce the number of EMB performed during the follow-up of the transplanted patient. The aim of the present work was to study the potential relationship between rejection and serum concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) as well as cardiac troponin T (cTnT) in post-transplantation patients. nnMethods: Twenty-three consecutive orthotopic heart transplantation recipients with a mean age of 51 years (range 22-66) were prospectively recruited from the cardiac transplantation programme at the Hospital Universitario Central de Asturias. Serum NT-proBNP and cTnT were measured during the follow-up of these patients (ranging from 9-13 months post-transplantation) and compared with the results of EMB. nnResults: Serum NT-proBNP concentrations progressively decrease during the first year post-transplantation, reaching concentrations slightly higher than the reference values. NT-proBNP concentrations increase significantly in those patients with a rejection episode graded 3A on the basis of the EMB (P < 0.001, Mann-Whitney U-test). No relation between cTnT and rejection was observed. nnConclusions: The potential of NT-proBNP as a non-invasive marker of transplantation rejection shows promising results, since NT-proBNP concentrations increase whenever a significant rejection event takes place in the first year of follow-up.
机译:移植是心力衰竭患者的主要姑息治疗。心脏排斥反应的临床体征可能非常非特异性甚至不存在。因此,成功的治疗依赖于早期诊断,最好是在出现心脏功能障碍的临床特征之前。尽管心内膜活检(EMB)是参考诊断方法,但已提出了几种非侵入性方法来减少在移植患者的随访期间进行的EMB数量。本研究的目的是研究移植后患者排斥反应与血清N端前脑利钠肽(NT-proBNP)以及心肌肌钙蛋白T(cTnT)的潜在关系。方法:前瞻性从阿斯图里亚斯中央大学医院的心脏移植计划中招募二十三名平均年龄为51岁(范围22-66)的连续原位心脏移植受者。在这些患者的随访期间(移植后9-13个月)测量血清NT-proBNP和cTnT,并与EMB结果进行比较。结果:在移植后的第一年中,血清NT-proBNP的浓度逐渐降低,达到的浓度略高于参考值。在基于EMB的3A级排斥反应患者中,NT-proBNP浓度显着增加(P <0.001,Mann-Whitney U检验)。没有观察到cTnT与排斥反应之间的关系。结论:NT-proBNP作为移植排斥的非侵入性标志物的潜力显示出令人鼓舞的结果,因为在随访的第一年中,只要发生重大排斥事件,NT-proBNP的浓度就会增加。

著录项

  • 来源
    《Annals of Clinical Biochemistry》 |2007年第2期|p.182-188|共7页
  • 作者单位

    Servicio de Bioquímica Clinica, Hospital Universitario Central de Asturias, Oviedo, Spain;

    Servicio de Cardiología, Hospital Universitario Central de Asturias, c/Celestino Villamil, Oviedo, Spain;

    Departamento de Bioquímica y Biología Molecular, Universidad de Oviedo, Oviedo, Spain;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 14:14:05

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号